198 related articles for article (PubMed ID: 38339929)
1. The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Li Z; Fan Z; Zhang Q
J Alzheimers Dis; 2024; 98(1):13-32. PubMed ID: 38339929
[TBL] [Abstract][Full Text] [Related]
2. Event-related Potentials Improve the Efficiency of Cerebrospinal Fluid Biomarkers for Differential Diagnosis of Alzheimer's Disease.
Babić Leko M; Krbot Skorić M; Klepac N; Borovečki F; Langer Horvat L; Vogrinc Ž; Sonicki Z; Hof PR; Šimić G
Curr Alzheimer Res; 2018; 15(13):1244-1260. PubMed ID: 30207231
[TBL] [Abstract][Full Text] [Related]
3. Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.
Babić Leko M; Borovečki F; Dejanović N; Hof PR; Šimić G
J Alzheimers Dis; 2016; 50(3):765-78. PubMed ID: 26836160
[TBL] [Abstract][Full Text] [Related]
4. Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology.
Silva-Spínola A; Leitão MJ; Nadal A; Le Bastard N; Santana I; Baldeiras I
Alzheimers Res Ther; 2024 Mar; 16(1):51. PubMed ID: 38454502
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal Fluid Alzheimer's Disease Biomarker Patterns of Change Prior to the Onset of Mild Cognitive Impairment.
Sun Y; Moghekar A; Soldan A; Pettigrew C; Greenberg B; Albert M; Wang MC;
J Alzheimers Dis; 2023; 96(1):287-300. PubMed ID: 37742656
[TBL] [Abstract][Full Text] [Related]
6. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
Gleason CE; Norton D; Anderson ED; Wahoske M; Washington DT; Umucu E; Koscik RL; Dowling NM; Johnson SC; Carlsson CM; Asthana S;
J Alzheimers Dis; 2018; 61(1):79-89. PubMed ID: 29125485
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort.
Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Janelidze S; Zetterberg H; Scheffler M; Assal F; Garibotto V; Blennow K; Hansson O; Frisoni GB
J Neurol; 2024 Apr; 271(4):2053-2066. PubMed ID: 38195896
[TBL] [Abstract][Full Text] [Related]
8. Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease.
Pilotto A; Parigi M; Bonzi G; Battaglio B; Ferrari E; Mensi L; Benussi A; Caratozzolo S; Cosseddu M; Turrone R; Archetti S; Ashton NJ; Zetterberg H; Giliani S; Padovani A
J Alzheimers Dis; 2022; 87(3):991-997. PubMed ID: 35404280
[TBL] [Abstract][Full Text] [Related]
9. Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts.
Lantero-Rodriguez J; Vrillon A; Fernández-Lebrero A; Ortiz-Romero P; Snellman A; Montoliu-Gaya L; Brum WS; Cognat E; Dumurgier J; Puig-Pijoan A; Navalpotro-Gómez I; García-Escobar G; Karikari TK; Vanmechelen E; Ashton NJ; Zetterberg H; Suárez-Calvet M; Paquet C; Blennow K
Alzheimers Res Ther; 2023 Mar; 15(1):48. PubMed ID: 36899441
[TBL] [Abstract][Full Text] [Related]
10. Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.
Spiegel J; Pirraglia E; Osorio RS; Glodzik L; Li Y; Tsui W; Saint Louis LA; Randall C; Butler T; Xu J; Zinkowski RP; Zetterberg H; Fortea J; Fossati S; Wisniewski T; Davies P; Blennow K; de Leon MJ
J Alzheimers Dis; 2016; 49(1):93-100. PubMed ID: 26444757
[TBL] [Abstract][Full Text] [Related]
11. Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP.
Wojdała AL; Bellomo G; Gaetani L; Toja A; Chipi E; Shan D; Chiasserini D; Parnetti L
Neurobiol Dis; 2023 Dec; 189():106356. PubMed ID: 37977432
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease.
Kac PR; Gonzalez-Ortiz F; Simrén J; Dewit N; Vanmechelen E; Zetterberg H; Blennow K; Ashton NJ; Karikari TK
Alzheimers Res Ther; 2022 May; 14(1):65. PubMed ID: 35545792
[TBL] [Abstract][Full Text] [Related]
13. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
[TBL] [Abstract][Full Text] [Related]
14. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment.
Liu W; Lin H; He X; Chen L; Dai Y; Jia W; Xue X; Tao J; Chen L
Transl Psychiatry; 2020 Apr; 10(1):125. PubMed ID: 32350238
[TBL] [Abstract][Full Text] [Related]
15. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.
Gonzalez MC; Ashton NJ; Gomes BF; Tovar-Rios DA; Blanc F; Karikari TK; Mollenhauer B; Pilotto A; Lemstra A; Paquet C; Abdelnour C; Kramberger MG; Bonanni L; Vandenberghe R; Hye A; Blennow K; Zetterberg H; Aarsland D;
JAMA Neurol; 2022 Jan; 79(1):32-37. PubMed ID: 34807233
[TBL] [Abstract][Full Text] [Related]
16. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
[TBL] [Abstract][Full Text] [Related]
17. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.
Ashton NJ; Puig-Pijoan A; Milà-Alomà M; Fernández-Lebrero A; García-Escobar G; González-Ortiz F; Kac PR; Brum WS; Benedet AL; Lantero-Rodriguez J; Day TA; Vanbrabant J; Stoops E; Vanmechelen E; Triana-Baltzer G; Moughadam S; Kolb H; Ortiz-Romero P; Karikari TK; Minguillon C; Hernández Sánchez JJ; Navalpotro-Gómez I; Grau-Rivera O; María Manero R; Puente-Periz V; de la Torre R; Roquer J; Dage JL; Zetterberg H; Blennow K; Suárez-Calvet M
Alzheimers Dement; 2023 May; 19(5):1913-1924. PubMed ID: 36370462
[TBL] [Abstract][Full Text] [Related]
18. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.
Ashton NJ; Pascoal TA; Karikari TK; Benedet AL; Lantero-Rodriguez J; Brinkmalm G; Snellman A; Schöll M; Troakes C; Hye A; Gauthier S; Vanmechelen E; Zetterberg H; Rosa-Neto P; Blennow K
Acta Neuropathol; 2021 May; 141(5):709-724. PubMed ID: 33585983
[TBL] [Abstract][Full Text] [Related]
19. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
[TBL] [Abstract][Full Text] [Related]
20. The performance of plasma phosphorylated tau231 in detecting Alzheimer's disease: A systematic review with meta-analysis.
Xu C; Zhao L; Dong C
Eur J Neurosci; 2023 Aug; 58(4):3132-3149. PubMed ID: 37501373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
